Clinical Research Directory
Browse clinical research sites, groups, and studies.
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
Sponsor: PharmaIN
Summary
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.
Official title: A Phase 1 Open Label Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PHIN-214 in Adults With Child Pugh A and B Cirrhosis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
74
Start Date
2022-01-03
Completion Date
2026-06-30
Last Updated
2025-09-05
Healthy Volunteers
No
Interventions
PHIN-214 Subcutaneous injection
subcutaneous injection(s) with PHIN-214 terlipressin derivative
Locations (9)
Arizona Liver Health
Chandler, Arizona, United States
Southern California Research Center
Coronado, California, United States
Tandem Clinical Research
Marrero, Louisiana, United States
Mayo Clinic
Rochester, Minnesota, United States
Cleveland Clinic
Cleveland, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Methodist Health System, Dallas Medical Center
Dallas, Texas, United States
VA North Texas Healthcare System
Dallas, Texas, United States
Texas Liver Institute
San Antonio, Texas, United States